Vitruvias Therapeutics Inc., a pharmaceutical company that manufactures thyroid hormone replacement, announced a voluntary recall of one lot of its 30 mg USP thyroid tablets. The recall follows internal testing that indicated the tablets could be “superpotent,” meaning they may contain more active ingredient than the label specifies.
Why the recall matters
Thyroid medication is prescribed to treat hypothyroidism, a condition in which the thyroid gland does not produce enough hormone. If a dose is too strong, patients can develop hyperthyroidism, an overactive thyroid that can cause rapid heart rate, anxiety, weight loss, and other serious health effects. The company warned that the excess potency could trigger these symptoms, particularly in groups that are more vulnerable: older adults, pregnant women and infants.
Details of the affected lot
The recalled lot is identified by the number 504950. Tablets from this lot were distributed between January 31 and September 30, 2025, and carry an expiration date of September 30, 2026. Vitruvias has not received any reports of adverse events linked to this specific recall, but it is taking precautionary action to protect patients.
What patients should do
Anyone currently taking Vitruvias 30 mg thyroid tablets from the recalled lot should not stop the medication abruptly. The company advises patients to contact their healthcare provider for guidance and, if necessary, a replacement prescription. Health professionals can verify the lot number on the packaging and determine whether a switch to a different batch or brand is appropriate.
Regulatory context
Recalls of prescription drugs are overseen by the U.S. Food and Drug Administration (FDA). While Vitruvias initiated the recall voluntarily, the FDA monitors such actions to ensure manufacturers comply with safety standards. This recall underscores the importance of rigorous quality control in the pharmaceutical industry, especially for medications that affect hormone balance.
Broader implications
Thyroid disorders affect millions of Americans, and thyroid hormone replacement is a cornerstone of treatment for many. Ensuring the correct dosage is critical not only for individual health but also for public confidence in prescription medicines. The recall serves as a reminder for patients to keep records of lot numbers and expiration dates, and to maintain open communication with their doctors.
Vitruvias Therapeutics stated that it will continue to investigate the cause of the potency discrepancy and implement corrective measures to prevent future occurrences. The company reaffirmed its commitment to patient safety and to delivering reliable, high‑quality medication.
Original reporting: KOAT Albuquerque — read the source article.
